Research map: Disease Course After Anti‐ CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Back to the article

Papers in this map

  1. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria · Alan J. Thompson · 2017 · 8286 citations · Cited by this paper
  2. Interaction of Intraprocedural Antiplatelets and Intravenous Thrombolysis in Acute Intracranial Stenting: RESISTANT Registry Subanalysis · 2026 · Related
  3. Defining the clinical course of multiple sclerosis · FRED D. LUBLIN · 2014 · 3207 citations · Cited by this paper
  4. Neurologic Manifestations of Long COVID Affect Adult Females More Severely Than Males · 2026 · Related
  5. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis · Stephen L. Hauser · 2008 · 2448 citations · Cited by this paper
  6. Integrated PANoptosis Profiling Identifies Immunosuppressive Subtypes and a Prognostic Signature With Functional Validation of MLKL in Glioblastoma · 2026 · Related
  7. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis · Stephen L. Hauser · 2016 · 2046 citations · Cited by this paper
  8. Electroencephalographic Normalization as a Biomarker of Clinical Recovery in Down Syndrome Regression Disorder · 2026 · Related
  9. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 · ME Reff · 1994 · 1947 citations · Cited by this paper
  10. Intracerebral Hemorrhage Induces Monocyte TNF Signaling in Patients That Is Suppressed by BAF 312 · 2026 · Related
  11. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis · Xavier Montalbán · 2016 · 1919 citations · Cited by this paper
  12. Characterizing Cutaneous α‐Synuclein Deposition and Seeding Activity in Parkinson's Disease Subtypes · 2026 · Related
  13. Ageing and multiple sclerosis · Jennifer S. Graves · 2022 · 262 citations · Cited by this paper
  14. Modern Management of Asymptomatic Carotid Stenosis: A Meta‐Analysis of CREST ‐2, SPACE ‐2, and ECST ‐2 · 2026 · Related
  15. ECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis · Xavier Montalbán · 2018 · 228 citations · Cited by this paper
  16. Evaluation of Dried Plasma Spot‐Based Quantification of Glial Fibrillary Acidic Protein as a Disease‐Associated Biomarker in Neuromyelitis Optica Spectrum Disorder · 2026 · Related
  17. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management · Mark Steven Freedman · 2024 · 200 citations · Cited by this paper
  18. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis · Stephen L. Hauser · 2021 · 193 citations · Cited by this paper
  19. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial · 信雄 大石 · 2023 · 154 citations · Cited by this paper
  20. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis · Yvonne Naegelin · 2019 · 78 citations · Cited by this paper
  21. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS · Guillaume Jouvenot · 2024 · 60 citations · Cited by this paper
  22. Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation · Arie Gafson · 2022 · 50 citations · Cited by this paper
  23. Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity · Anne-Laure Kaminsky · 2020 · 37 citations · Cited by this paper
  24. Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials · Tobias J Derfuss · 2024 · 26 citations · Cited by this paper
  25. Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review · Óscar Fernández · 2024 · 24 citations · Cited by this paper
  26. Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials · Ludwig Kappos · 2025 · 21 citations · Cited by this paper
  27. Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study · Tobias Moser · 2022 · 14 citations · Cited by this paper
  28. The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis · E.M.E. Coerver · 2024 · 9 citations · Cited by this paper
  29. Radiological Disease Activity in Secondary Progressive Multiple Sclerosis · Daniela Noa Zohar · 2023 · 4 citations · Cited by this paper
  30. Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity · Franz Felix Konen · 2026 · 4 citations · Cited by this paper
  31. Intrathecal Immunoglobulin A Synthesis in Multiple Sclerosis: From Biological Aspects to Clinical Relevance · Dariia Kliushnikova · 2025 · 4 citations · Cited by this paper
  32. Rituximab in secondary progressive multiple sclerosis: a meta‐analysis · Pasin Intarakhao · 2024 · 2 citations · Cited by this paper
  33. Untitled · Cited by this paper

Source: OpenAlex (CC0)